⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Lavipharm SA and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Lavipharm SA
↗Paiania, Greece
Lavipharm is a Greece-based international pharmaceutical company founded in 1911. It specializes in the research, development, manufacturing, and distribution of prescription medicines (Rx), over-the-counter (OTC) products, and dermocosmetics, with a strong emphasis on transdermal drug delivery systems (TDDS).
The company operates as both a commercial pharmaceutical enterprise and a CDMO, providing services for transdermal, liquid, and semi-solid formulations. Its core therapeutic focus areas include cardiometabolic health, oncology, urology, central nervous system (CNS) disorders, and chronic pain management.
CLASSIFICATION
Company Type:CDMO
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Diversified Pharmaceuticals / CDMO
SIZE & FINANCIALS
Employees:51-200
Revenue:$70M-$75M
Founded:1911
Ownership:public
Status:operating
STOCK
Exchange:Athens Stock Exchange
Ticker:LAVI
Market Cap:$0.33B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Transdermal systems
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Lavipharm Hellas, Pharma Logistics
Key Partnerships:Teva, Sandoz, Zentiva, Chiesi, Mundipharma, Neuraxpharm
COMPETITION
Position:Niche Player
Competitors:Pharmathen, Galenica, Win Medica
LEADERSHIP
Key Executives:
Nikolaos Ladas - Chief Scientific Officer
Ioannis Sarigiannidis - Chief Commercial Officer International
LINKS
Website:lavipharm.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Lavipharm SA. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.